The use of recent techniques such as next-generation sequencing (NGS) has defined panels of genetic abnormalities peculiar to MPN (comprising genes such as TP53, SF3B1, SRSF2, TET2, PTPN11, IDH2, EZH2, DNMT3A and others). This evidence concerns the gene TP53 and myeloproliferative neoplasm.